uniQure (NASDAQ:QURE) Price Target Raised to $110.00 at HC Wainwright

uniQure (NASDAQ:QURE) had its price target boosted by stock analysts at HC Wainwright from $70.00 to $110.00 in a research note issued on Monday,Benzinga reports. The firm currently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price objective points to a potential upside of 100.29% from the stock’s current price.

A number of other analysts have also weighed in on the stock. Leerink Partners raised their target price on shares of uniQure from $48.00 to $68.00 and gave the company an “outperform” rating in a research report on Wednesday, September 24th. Chardan Capital increased their price target on uniQure from $35.00 to $76.00 and gave the company a “buy” rating in a research report on Thursday, September 25th. UBS Group set a $95.00 price target on shares of uniQure in a research report on Thursday, September 25th. Wells Fargo & Company lifted their price objective on shares of uniQure from $65.00 to $80.00 and gave the company an “overweight” rating in a research note on Thursday. Finally, Cantor Fitzgerald raised their price target on uniQure from $47.00 to $80.00 and gave the company an “overweight” rating in a report on Thursday, September 25th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $71.75.

uniQure Price Performance

uniQure stock opened at $54.92 on Monday. The business has a 50-day moving average of $21.59 and a 200-day moving average of $16.40. uniQure has a 1 year low of $4.82 and a 1 year high of $60.70. The firm has a market capitalization of $3.01 billion, a P/E ratio of -14.01 and a beta of 0.56. The company has a current ratio of 9.98, a quick ratio of 9.98 and a debt-to-equity ratio of 1.53.

uniQure (NASDAQ:QURE) last released its quarterly earnings results on Tuesday, July 29th. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.89) by $0.20. The firm had revenue of $5.26 million for the quarter, compared to the consensus estimate of $5.00 million. uniQure had a negative return on equity of 1,010.74% and a negative net margin of 1,387.98%. On average, equities analysts anticipate that uniQure will post -3.75 EPS for the current year.

Insider Transactions at uniQure

In related news, CEO Matthew C. Kapusta sold 226,316 shares of the firm’s stock in a transaction that occurred on Wednesday, September 24th. The stock was sold at an average price of $41.46, for a total value of $9,383,061.36. Following the transaction, the chief executive officer directly owned 651,454 shares of the company’s stock, valued at approximately $27,009,282.84. This trade represents a 25.78% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Christian Klemt sold 15,000 shares of the business’s stock in a transaction on Friday, September 26th. The stock was sold at an average price of $55.00, for a total transaction of $825,000.00. Following the transaction, the chief financial officer directly owned 217,730 shares in the company, valued at $11,975,150. This trade represents a 6.45% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 244,316 shares of company stock worth $10,328,181 over the last 90 days. 4.79% of the stock is owned by insiders.

Institutional Trading of uniQure

A number of institutional investors have recently bought and sold shares of QURE. Jefferies Financial Group Inc. acquired a new stake in uniQure during the 2nd quarter worth approximately $29,217,000. Vestal Point Capital LP boosted its position in shares of uniQure by 58.4% during the first quarter. Vestal Point Capital LP now owns 4,792,572 shares of the biotechnology company’s stock valued at $50,801,000 after buying an additional 1,767,572 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in uniQure by 471.7% during the second quarter. JPMorgan Chase & Co. now owns 1,807,685 shares of the biotechnology company’s stock worth $25,199,000 after purchasing an additional 1,491,486 shares during the last quarter. Sofinnova Investments Inc. increased its holdings in uniQure by 185.5% during the second quarter. Sofinnova Investments Inc. now owns 1,558,356 shares of the biotechnology company’s stock worth $21,723,000 after buying an additional 1,012,585 shares during the last quarter. Finally, Aberdeen Group plc raised its stake in uniQure by 46.8% in the 1st quarter. Aberdeen Group plc now owns 2,215,551 shares of the biotechnology company’s stock valued at $23,485,000 after acquiring an additional 706,216 shares during the period. Institutional investors own 78.83% of the company’s stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.